Page 26 - Research Models News Today

Charles River Laboratories International (NYSE:CRL – Get Rating) updated its FY 2023 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $9.90-$10.90 for the period, compared to the consensus estimate of $10.24. The company issued revenue guidance of $4.06 billion-$4.16 billion, compared to the consensus revenue estimate of $4.09 billion. Analyst […]

Updates Select Full Year Fiscal 2023 Financial GuidanceWEST LAFAYETTE, Ind., May 11, 2023 -- Inotiv, Inc. , a leading contract research organization specializing in nonclinical and analytical drug... | May 11, 2023

Charles River Laboratories International (NYSE:CRL – Get Rating) will be issuing its quarterly earnings data before the market opens on Thursday, May 11th. Analysts expect the company to announce earnings of $2.59 per share for the quarter. Charles River Laboratories International has set its FY23 guidance at $9.70-10.90 EPS and its FY 2023 guidance at […]

Premier Fund Managers Ltd boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 98.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 220,000 shares of the medical research company’s stock after buying an additional […]

StockNews.com cut shares of Charles River Laboratories International (NYSE:CRL – Get Rating) from a buy rating to a hold rating in a report issued on Friday morning. A number of other research firms have also recently commented on CRL. Jefferies Financial Group lowered their price target on shares of Charles River Laboratories International from $233.00 […]

Alliance Wealth Advisors LLC UT bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,236 shares of the medical research company’s stock, valued at approximately $269,000. A number of other institutional […]

Retirement Systems of Alabama lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 3.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,301 shares of the medical research company’s stock after selling 593 shares during the period. Retirement […]

Shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) – Zacks Research lowered their FY2025 EPS estimates for shares of Charles River Laboratories International in a research note issued on Wednesday, May 3rd. Zacks Research analyst U. Biswas now expects that the medical research company will earn $14.48 per share for the year, down from […]

Jensen Investment Management Inc. raised its position in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 32.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,080 shares of the medical research company’s stock after acquiring an additional 5,710 […]